What is the 13F Pro Quality Score for RMTI?

13F Pro ranks ROCKWELL MEDICAL, INC. (RMTI) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View RMTI's current score at https://13fpro.ai/research/RMTI (free sign-up required for the full ranking).

Where does 13F Pro source RMTI data?

All ROCKWELL MEDICAL, INC. fundamentals and ownership data come directly from SEC EDGAR. ROCKWELL MEDICAL, INC. files with the SEC under CIK 1041024. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is RMTI in?

ROCKWELL MEDICAL, INC. (RMTI) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is RMTI research updated on 13F Pro?

RMTI's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

ROCKWELL MEDICAL, INC.(RMTI)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1041024 RMTI stock profile & AI dashboard →

13F Pro Quality Score

20.5/100

Rank #2,674 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

12.3/100

Profitability

19.5/100

Balance Sheet

16.4/100

Earnings Quality

30.0/100

Free Cash Flow

22.7/100

Institutional Flow

57.9/100

Revenue Scale

13.8/100

Dilution Risk

36.6/100

RMTI Stock Analysis & AI Quality Score

AI stock analysis and institutional research for ROCKWELL MEDICAL, INC. (RMTI), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RMTI at 20.5/100 on a 32-signal composite quality model, placing it at rank #2,674 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (12.3) and revenue scale (13.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 36.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), ROCKWELL MEDICAL, INC. reports quarterly revenue of $17.3M, net income of $-1.6M, an operating margin of -8.5%. Top institutional holders of RMTI by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, RENAISSANCE TECHNOLOGIES, GEODE CAPITAL MANAGEMENT,, based on the most recent SEC filings. RMTI trades on the Nasdaq exchange and files with the SEC under CIK 1041024. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RMTI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ROCKWELL MEDICAL, INC. directly from SEC EDGAR. ROCKWELL MEDICAL, INC.'s 13F Pro composite quality score has ranged between 13 and 43 since 2021, currently 20.5 — a stable long-term trajectory across 28 quarterly and live scoring snapshots.

✦

Fun facts about ROCKWELL MEDICAL, INC.

Quirks, history, and lore behind RMTI — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. specialty pharmaceutical company · small-cap · listed on Nasdaq · headquartered in Michigan.
2
The Numbers
Annual revenue in the range of roughly $70–80 million — not a blockbuster, but a focused niche player whose products serve a very specific and life-sustaining patient population.
3
The History
Founded in the 1990s, the company spent years developing proprietary formulations and eventually secured FDA approval for treatments used directly at dialysis clinics across the country.
4
The Secret
Its core business is supplying iron and dialysis concentrate solutions to the roughly 500,000 Americans who rely on kidney dialysis to survive each week.
5
The Lore
The company distributes its products through a network of dialysis centers and has tangled with larger rivals like DaVita and Fresenius for supply contracts — a classic David-vs-Goliath niche play.
6
The Giveaway
Its flagship intravenous iron product Triferic delivers iron directly through the dialysate during every hemodialysis session — a delivery method unlike anything else on the market.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$17.3M

Net Income

Q1 2026

$-1.6M

Free Cash Flow

Q1 2026

$-592.0K

Operating Margin

Q1 2026

-8.5%

D/E Ratio

Q1 2026

0.25

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-31.8% YoY

$69.3MFY 2025

FY22 $72.8MFY23 $83.6MFY24 $101.5MFY25 $69.3M

Net Income

-1007.1% YoY

$-5.3MFY 2025

FY22 $-18.7MFY23 $-8.4MFY24 $-480.0KFY25 $-5.3M

Operating Income

-871.5% YoY

$-4.7MFY 2025

FY22 $-16.8MFY23 $-6.7MFY24 $608.0KFY25 $-4.7M

EPS (Diluted)

-400.0% YoY

$-0.15FY 2025

FY22 $-1.31FY23 $-0.37FY24 $-0.03FY25 $-0.15

Total Assets

-3.5% YoY

$57.1MFY 2025

FY22 $46.6MFY23 $52.2MFY24 $59.2MFY25 $57.1M

Total Debt

+4.2% YoY

$8.8MFY 2025

FY22 $9.2MFY23 $8.3MFY24 $8.5MFY25 $8.8M

Op. Cash Flow

-115.7% YoY

$-659.0KFY 2025

FY22 $-16.9MFY23 $-9.4MFY24 $4.2MFY25 $-659.0K

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2020	FY 2018
Revenue	$69.3M -31.8%	$101.5M +21.4%	$83.6M +14.8%	$72.8M +17.1%	$62.2M -1.9%	$63.4M
Net Income	$-5.3M -1007.1%	$-480.0K +94.3%	$-8.4M +54.8%	$-18.7M +39.5%	$-30.9M +3.8%	$-32.1M
Operating Income	$-4.7M -871.5%	$608.0K +109.1%	$-6.7M +60.3%	$-16.8M +41.0%	$-28.4M +12.4%	$-32.4M
EPS (Diluted)	$-0.15 -400.0%	$-0.03 +91.9%	$-0.37 +71.8%	$-1.31 -219.5%	$-0.41	—
Total Assets	$57.1M -3.5%	$59.2M +13.5%	$52.2M +11.9%	$46.6M -40.0%	$77.7M +47.9%	$52.6M
Total Debt	$8.8M +4.2%	$8.5M +2.2%	$8.3M -9.7%	$9.2M -56.2%	$20.9M	—
Operating Cash Flow	$-659.0K -115.7%	$4.2M +144.6%	$-9.4M +44.4%	$-16.9M +42.9%	$-29.6M -45.2%	$-20.4M

AI Insight: RMTI Ratio Trends

Rockwell Medical slipped back into deep losses across all profitability metrics in Q1 2026, erasing Q4 2025's brief respite.

• Operating margin collapsed to -8.5% in Q1 2026 from -2.2% in Q4 2025; NPM fell to -9.3% from -3.0%.

• ROE deteriorated to -17.9% in Q1 2026 versus -6.0% prior quarter; ROIC worsened to -13.2% from -3.5%.

• Debt-to-equity held steady at 0.24–0.28 range; leverage remained stable despite persistent unprofitability.

⚠ Q4 2025 showed isolated profitability improvement (OpMargin -2.2%, ROE -6.0%) but failed to persist; pattern suggests seasonal or one-off gain.

⚠ TTM metrics show company deeply underwater: -7.1% OpMargin, -10.8% ROIC; no sustained return to positive returns since Q3 2024.

Get alerted when RMTI's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ROCKWELL MEDICAL, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of RMTI

VANGUARD CAPITAL MANAGEMENT LLC
$1.1M1,182,361 sh
RENAISSANCE TECHNOLOGIES LLC
$570.9K639,120 sh
GEODE CAPITAL MANAGEMENT, LLC
$383.4K429,180 sh
BlackRock, Inc.
$211.4K236,671 sh
VANGUARD FIDUCIARY TRUST CO
$206.5K231,258 sh
UBS Group AG
$159.7K178,886 sh
Wealthspire Advisors, LLC
$135.6K151,838 sh
NORTHERN TRUST CORP
$93.4K104,523 sh
STATE STREET CORP
$90.1K100,904 sh
HighTower Advisors, LLC
$83.5K93,524 sh

Fund	Value	Shares
VANGUARD CAPITAL MANAGEMENT LLC	$1.1M	1,182,361
RENAISSANCE TECHNOLOGIES LLC	$570.9K	639,120
GEODE CAPITAL MANAGEMENT, LLC	$383.4K	429,180
BlackRock, Inc.	$211.4K	236,671
VANGUARD FIDUCIARY TRUST CO	$206.5K	231,258
UBS Group AG	$159.7K	178,886
Wealthspire Advisors, LLC	$135.6K	151,838
NORTHERN TRUST CORP	$93.4K	104,523
STATE STREET CORP	$90.1K	100,904
HighTower Advisors, LLC	$83.5K	93,524

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put RMTI on your watchlist

Track score changes the day ROCKWELL MEDICAL, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is RMTI a good stock to buy?

13F Pro's AI-powered analysis of ROCKWELL MEDICAL, INC. (RMTI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RMTI are available on the RMTI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own RMTI?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RMTI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ROCKWELL MEDICAL, INC.'s investment landscape.